{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T03:05:21Z","timestamp":1791687921976,"version":"4.3.4"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472021"],"award-info":[{"award-number":["82472021"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031934","name":"First Affiliated Hospital of Xi'an Jiaotong University","doi-asserted-by":"publisher","award":["2024jbgs-01"],"award-info":[{"award-number":["2024jbgs-01"]}],"id":[{"id":"10.13039\/100031934","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2024SF-ZDCYL-02-07"],"award-info":[{"award-number":["2024SF-ZDCYL-02-07"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015401","name":"Key Research and Development Projects of Shaanxi Province","doi-asserted-by":"publisher","award":["2025TD-08"],"award-info":[{"award-number":["2025TD-08"]}],"id":[{"id":"10.13039\/501100015401","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.jconrel.2026.115276","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T23:36:30Z","timestamp":1787268990000},"page":"115276","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Preclinical and first-in-human pilot evaluation of 177Lu-DOTA-7ND for fibroblast activation protein-\u03b1-targeted radionuclide imaging and therapy"],"prefix":"10.1016","volume":"398","author":[{"given":"Yiqian","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haojun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinru","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixing","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jconrel.2026.115276_bb0005","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers15030908","article-title":"PET\/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application \u2014 a literature review","volume":"15","author":"Taralli","year":"2023","journal-title":"Cancers"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115276_bb0010","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: tracer uptake in 28 different kinds of cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115276_bb0015","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1007\/s00259-023-06272-7","article-title":"Head-to-head comparison of different classes of FAP radioligands designed to increase tumor residence time: monomer, dimer, albumin binders, and small molecules vs peptides","volume":"50","author":"Millul","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115276_bb0020","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Prive","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"13","key":"10.1016\/j.jconrel.2026.115276_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29133093","article-title":"Tailoring fibroblast-activation protein targeting for theranostics: a comparative preclinical evaluation of the (68)Ga- and (177)Lu-labeled monomeric and dimeric fibroblast-activation protein inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)(2)","volume":"29","author":"Lappchen","year":"2024","journal-title":"Molecules"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115276_bb0030","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol. Pharm."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115276_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121212","article-title":"First-in-human results on the biodistribution, pharmacokinetics, and dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115276_bb0040","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115276_bb0045","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.2967\/jnumed.120.242958","article-title":"Targeting fibroblast activation protein: radiosynthesis and preclinical evaluation of an (18)F-Labeled FAP inhibitor","volume":"61","author":"Toms","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115276_bb0050","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1007\/s00259-019-04444-y","article-title":"IDH-wildtype glioblastomas and grade III\/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET\/CT","volume":"46","author":"R\u00f6hrich","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115276_bb0055","doi-asserted-by":"crossref","first-page":"952","DOI":"10.2967\/jnumed.121.262533","article-title":"Albumin binder-conjugated fibroblast activation protein inhibitor radiopharmaceuticals for cancer therapy","volume":"63","author":"Xu","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115276_bb0060","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.123.265599","article-title":"Development of FAPI tetramers to improve tumor uptake and efficacy of FAPI radioligand therapy","volume":"64","author":"Pang","year":"2023","journal-title":"J. Nucl. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115276_bb0065","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1007\/s00259-023-06300-6","article-title":"An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy","volume":"50","author":"Xu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115276_bb0070","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1007\/s00259-023-06285-2","article-title":"Translational assessment of a DATA-functionalized FAP inhibitor with facile (68)Ga-labeling at room temperature","volume":"50","author":"Escudero-Castellanos","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"11","key":"10.1016\/j.jconrel.2026.115276_bb0075","first-page":"1665","article-title":"A pipeline for automated voxel dosimetry: application in patients with multi-SPECT\/CT imaging after (177)Lu-peptide receptor radionuclide therapy","volume":"63","author":"Dewaraja","year":"2022","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115276_bb0080","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.2967\/jnumed.119.236786","article-title":"Radiation dosimetry and biodistribution of 68Ga-FAPI-46 PET imaging in cancer patients","volume":"61","author":"Meyer","year":"2020","journal-title":"J. Nucl. Med."},{"issue":"19","key":"10.1016\/j.jconrel.2026.115276_bb0085","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and efficacy of 90Y-FAPI-46 radioligand therapy in patients with advanced sarcoma and other cancer entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115276_bb0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1097\/RLU.0000000000003667","article-title":"Safety of fibroblast activation protein-targeted radionuclide therapy by a low-dose dosimetric approach using 177Lu-FAPI04","volume":"46","author":"Kuyumcu","year":"2021","journal-title":"Clin. Nucl. Med."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115276_bb0095","doi-asserted-by":"crossref","first-page":"422","DOI":"10.7150\/thno.68182","article-title":"Evans blue-modified radiolabeled fibroblast activation protein inhibitor as long-acting cancer therapeutics","volume":"12","author":"Wen","year":"2022","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115276_bb0100","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","article-title":"Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy","volume":"49","author":"Zhang","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"23","key":"10.1016\/j.jconrel.2026.115276_bb0105","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115276_bb0110","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.120.248658","article-title":"Peptide receptor radionuclide therapy of late-stage neuroendocrine tumor patients with multiple cycles of (177)Lu-DOTA-EB-TATE","volume":"62","author":"Liu","year":"2021","journal-title":"J. Nucl. Med."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115276_bb0115","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1158\/1078-0432.CCR-24-3918","article-title":"177Lu-LNC1004 radioligand therapy in patients with end-stage metastatic cancers: a single-center, single-arm, phase II study","volume":"31","author":"Fu","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115276_bb0120","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115276_bb0125","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/s00259-024-06795-7","article-title":"Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma","volume":"52","author":"Banihashemian","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"10.1016\/j.jconrel.2026.115276_bb0130","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/RLU.0000000000005297","article-title":"Efficacy and safety evaluation of 177Lu-FAP-2286 in the treatment of advanced lung cancer","volume":"49","author":"Xie","year":"2024","journal-title":"Clin. Nucl. Med."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115276_bb0135","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1365-2559.2009.03399.x","article-title":"Histogenesis-specific expression of fibroblast activation protein and dipeptidylpeptidase-IV in human bone and soft tissue tumours","volume":"55","author":"Dohi","year":"2009","journal-title":"Histopathology"},{"key":"10.1016\/j.jconrel.2026.115276_bb0140","first-page":"0282","article-title":"Development and characterization of novel FAP-targeted theranostic pairs: a bench-to-bedside study","volume":"6","author":"Huang","year":"2023","journal-title":"Research (Wash DC)"},{"key":"10.1016\/j.jconrel.2026.115276_bb0145","doi-asserted-by":"crossref","first-page":"215","DOI":"10.3389\/fonc.2013.00215","article-title":"What is the role of the bystander response in radionuclide therapies?","volume":"3","author":"Brady","year":"2013","journal-title":"Front. Oncol."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115276_bb0150","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1016\/j.ccell.2024.08.011","article-title":"Classifying cancer-associated fibroblasts \u2014 the good, the bad, and the target","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.jconrel.2026.115276_bb0155","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.ccell.2023.12.021","article-title":"Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer","volume":"42","author":"Cords","year":"2024","journal-title":"Cancer Cell"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926006802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:02:49Z","timestamp":1790211769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926006802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":31,"alternative-id":["S0168365926006802"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115276","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Preclinical and first-in-human pilot evaluation of 177Lu-DOTA-7ND for fibroblast activation protein-\u03b1-targeted radionuclide imaging and therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115276","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"115276"}}